Kidney Function's Impact on Blood Levels of New Diabetes Drug NNC0480-0389
A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function
Background
Novo Nordisk is developing NNC0480-0389 as a novel therapy, intended for combination with semaglutide, to further enhance blood sugar control in patients with Type 2 Diabetes (T2D). Given that many individuals with T2D also experience varying degrees of renal impairment (reduced kidney function), it is crucial to understand how reduced kidney function impacts the pharmacokinetics (PK, or how the body handles the drug) of NNC0480-0389.
